Gujarat Themis Biosyn Ltd
Mon 24/11/2025,15:58:33 | NSE : GUJTHEM
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 409.80
Previous Close
₹ 412.70
Volume
81910
Mkt Cap ( Rs. Cr)
₹4362.97
High
₹ 412.15
Low
₹ 400.00
52 Week High
₹ 479.00
52 Week Low
₹ 208.00
Book Value Per Share
₹ 20.51
Dividend Yield
0.16
Face Value
₹ 1.00
What’s Your Call?
Collective community sentiment on Gujarat Themis Biosyn Ltd
Your Vote -
Buy
88.24%
Hold
0.00%
Sell
11.76%
88.24%
17 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
0%
Sell Order Quantity
100%
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Bid Price
Qty
400.40
60
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
60
Option Chain
Analyzes market sentiment, predicts Gujarat Themis Biosyn Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Guj. Themis Bios - Copy of Newspaper Publication
-
Guj. Themis Bios - Investor Presentation
-
Guj. Themis Bios - Announcement under Regulation 30 (LODR)-Investor Presentation
-
Guj. Themis Bios - Announcement under Regulation 30 (LODR)-Change in Management
-
Guj. Themis Bios - Appointment
-
Guj. Themis Bios - Outcome of Board Meeting
-
Guj. Themis Bios - Results - Un-Audited Financial Results For The Quarter And Half Year Ended 30Th September, 2025
-
Guj. Themis Bios Q2 net profit up 34.91% at Rs 14.26 cr
-
Guj. Themis Bios - Outcome of Board Meeting
-
Guj. Themis Bios - Board Meeting Outcome for Outcome Of The Board Meeting Under Regulation 30 Of The SEBI (Listing Obligation
-
Guj. Themis Bios - Board Meeting Intimation for Approval Of Un-Audited Financial Results For The Quarter And Half Year Ended
-
Guj. Themis Bios - Capacity addition
-
Guj. Themis Bios - Announcement Under Regulation 30 (LODR) - Commencement Of Commercial Production In Our New Fermentation Pl
-
Guj. Themis Bios has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2025
-
Guj. Themis Bios - Copy of Newspaper Publication
-
Guj. Themis Bios - Updates
-
Guj. Themis Bios - Report On Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares.
-
Guj. Themis Bios - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Guj. Themis Bios - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Guj. Themis Bios - Trading Window
-
Guj. Themis Bios - Announcement Under Regulation 30- Clarification
-
Guj. Themis Bios - Clarification sought from Gujarat Themis Biosyn Ltd
-
Guj. Themis Bios - Spurt in Volume
-
Guj. Themis Bios - Spurt in Volume
-
Guj. Themis Bios - General Updates
-
Guj. Themis Bios - Announcement Under Regulation 30 (Updates)
-
Guj. Themis Bios - Shareholders meeting
-
Guj. Themis Bios - Shareholder Meeting / Postal Ballot-Scrutinizer's Report
-
Guj. Themis Bios - Shareholders meeting
-
Guj. Themis Bios - Shareholder Meeting / Postal Ballot-Outcome of AGM
-
Guj. Themis Bios - Shareholder Meeting / Postal Ballot-Scrutinizer's Report
-
Guj. Themis Bios - Copy of Newspaper Publication
-
Guj. Themis Bios - Shareholder Meeting / Postal Ballot-Scrutinizer's Report
Key fundamentals
Evaluate the intrinsic value of Gujarat Themis Biosyn Ltd stock
| Name | March-25 | March-24 | March-23 | March-22 | March-21 |
|---|---|---|---|---|---|
| Assets | 278.2718 | 201.376 | 149.1459 | 103.3214 | 69.9472 |
| Liabilities | 278.2718 | 201.376 | 149.1459 | 103.3214 | 69.9472 |
| Equity | 10.8965 | 7.2644 | 7.2644 | 7.2644 | 7.2644 |
| Gross Profit | 68.8444 | 78.7337 | 74.2174 | 58.0452 | 39.4775 |
| Net Profit | 48.7717 | 59.1632 | 57.9688 | 43.6242 | 30.1797 |
| Cash From Operating Activities | 91.0286 | 64.213 | 39.5009 | 40.3132 | 6.0279 |
| NPM(%) | 32.34 | 34.83 | 38.91 | 37.98 | 33.32 |
| Revenue | 150.7999 | 169.8219 | 148.9729 | 114.8539 | 90.5627 |
| Expenses | 81.9555 | 91.0882 | 74.7555 | 56.8087 | 51.0852 |
| ROE(%) | 21.82 | 26.47 | 25.94 | 19.52 | 13.5 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|---|---|---|---|
| 04 Sep 2025 | 0.67 | 67 | 0.17 | 325.7 |
Peers
Other companies within the same industry or sector that are comparable to Gujarat Themis Biosyn Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 780.40 | -0.84 | 0.00 | 228.63 | 301.39 | 0.64 |
| Lotus Eye Hospital and Institute Ltd | 105.00 | -0.57 | 328.13 | 833.10 | 3.55 | 0.00 |
| Vaishali Pharma Ltd | 9.11 | -3.80 | 0.00 | 5226.31 | 3.13 | 0.00 |
| Astec Lifesciences Ltd | 890.00 | 7.36 | 0.00 | 785.63 | -604.77 | 0.00 |
Company Info
Gujarat Themis Biosyn Ltd. was incorporated in 1981 jointly by GIIC and chemosyn (P) Ltd. GIBL commenced production in Aug.1985 by producing antibiotic erythromycin, and erythromycin salts and formulations. GTBL was a sick company which was forced to discontinue production because of accumulated losses. The company was takenover during June 1991 by pharmaceutical Business Group India Ltd; a unique consortium of five competing drug companies - Themis Chemicals, Kopran, Anant & Co., Cadila and Lyka Labs. The company has technical and financial collaboration with Yuhan Corporation, South Korea. With Yuhan's knowhow, GTBL has become India's first company to start commercial production of anti-tubercolis drug, rifampicin. 2002-Gujarat Themis Biosyn Ltd has informed that Mr Rajneesh Anand has been appointed as the Managing Director of the Company w e f February 01, 2002. 2008 -Gujarat Themis Biosyn Ltd has appointed Mr. S S Lee as an Additional Director of the Company. -The Company has appointed Mr. Rajneesh Anand as Managing Director 2010 - Gujarat Themis Biosyn Ltd has appointed Mr. Subhash C Kaushik as Additional Director of the Company. 2011 -The Board of Directors appointed Mr. Rajneesh Anand as Managing Director of the Company 2012 -The Company has received a Rehabilitation Scheme approved by the Board of Industrial and Financial Reconstruction (BIFR) 2014 -Mr. Vikas Tarekar has been appointed as a Company Secretary of the company. -Mr. Tapas Guha has been appointed as a CEO of the Company. 2023 -The Company has splits its face value from Rs. 5/- to Rs. 1/-. 2024 -The Company has issued Bonus Shares in the Ratio of 1:2.
Gujarat Themis Biosyn Ltd. was incorporated in 1981 jointly by GIIC and chemosyn (P) Ltd. GIBL commenced production in Aug.1985 by producing antibiotic erythromycin, and erythromycin salts and formulations. GTBL was a sick company which was forced to discontinue production because of accumulated losses. The company was takenover during June 1991 by pharmaceutical Business Group India Ltd; a unique consortium of five competing drug companies - Themis Chemicals, Kopran, Anant & Co., Cadila and Lyka Labs. The company has technical and financial collaboration with Yuhan Corporation, South Korea. With Yuhan's knowhow, GTBL has become India's first company to start commercial production of anti-tubercolis drug, rifampicin. 2002-Gujarat Themis Biosyn Ltd has informed that Mr Rajneesh Anand has been appointed as the Managing Director of the Company w e f February 01, 2002. 2008 -Gujarat Themis Biosyn Ltd has appointed Mr. S S Lee as an Additional Director of the Company. -The Company has appointed Mr. Rajneesh Anand as Managing Director 2010 - Gujarat Themis Biosyn Ltd has appointed Mr. Subhash C Kaushik as Additional Director of the Company. 2011 -The Board of Directors appointed Mr. Rajneesh Anand as Managing Director of the Company 2012 -The Company has received a Rehabilitation Scheme approved by the Board of Industrial and Financial Reconstruction (BIFR) 2014 -Mr. Vikas Tarekar has been appointed as a Company Secretary of the company. -Mr. Tapas Guha has been appointed as a CEO of the Company. 2023 -The Company has splits its face value from Rs. 5/- to Rs. 1/-. 2024 -The Company has issued Bonus Shares in the Ratio of 1:2.
Read More
Parent Organisation
Gujarat Themis Biosyn Ltd.
Founded
11/12/1981
Managing Director
Dr.Sachin D Patel
NSE Symbol
GUJTHEMEQ
FAQ
The current price of Gujarat Themis Biosyn Ltd is ₹ 400.40.
The 52-week high for Gujarat Themis Biosyn Ltd is ₹ 412.15 and the 52-week low is ₹ 400.00.
The market capitalization of Gujarat Themis Biosyn Ltd is currently ₹ 4362.97. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Gujarat Themis Biosyn Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Gujarat Themis Biosyn Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Gujarat Themis Biosyn Ltd shares.
The CEO of Gujarat Themis Biosyn Ltd is Dr.Sachin D Patel, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
